Skip to main content
SpringerLink
Log in

Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Most changes of tumor suppressor p53 and its pathway involve a protein with prolonged half-life that permits immunohistochemical detection. The goal of this study was to compare the prognostic relevance of five different p53 antibodies in primary soft-tissue sarcomas (STS) with known p53 mutation status, using a multivariate Cox regression model (adjusted to tumor grading, staging, localization, tumor type, and therapy). A group of 198 primary STS of six types were investigated for p53 overexpression, using p53 antibodies DO-1, DO-7, Pab1801, Pab240, and CM-1. A positive marker frequency between 36.2% and 62.6% was detected. Out of 65 patients whose primary tumor reacted positively to all five antibodies, 52 (80%) died within the study period. Only the N-terminal-binding monoclonal antibodies DO-1, DO-7 and Pab1801 showed a multivariate correlation with survival (P=0.0014, 0.0048 and 0.02). CM-1 and Pab240 had a univariate, but not a multivariate correlation, with a confounding effect of grading. The prognostic relevance for the five p53 antibodies was: DO-1>Pab1801>DO-7>CM-1>Pab240. This is the first study that investigates multivariately the prognostic relevance of p53 immunostaining in STS. If monoclonal antibodies with an epitope in the N-terminal region of the p53 protein (DO-1, Pab1801, DO-7) are applied, p53 immunohistochemistry provides an independent prognostic marker in STS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

STS :

soft-tissue sarcoma

FS :

fibrosarcoma

LS :

liposarcoma

MFH :

malignant fibrous histiosarcoma

LMS :

leiomyosarcoma

MNT :

malignant neural tumor

RMS :

rhabdomyosarcoma

References

  • Bass IO, Mulder JWR, Offerhaus JA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12

    PubMed  Google Scholar 

  • Banks L, Matlashewski G, Crawford L (1986) Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 59:529–534

    Google Scholar 

  • Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP (1990) Patterns of expression of the p53 tumour suppressor in human breast tissue and tumours in situ and in vivo. Int J Cancer 46:839–844

    PubMed  Google Scholar 

  • Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6:1699–1703

    PubMed  Google Scholar 

  • Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GA, Taylor GL, Dixon MF, Quirke P (1993) Prognostic value of p53 overexpression and c-Ki-ras mutations in colorectal cancer. Gastroenterology 104:57–64

    PubMed  Google Scholar 

  • Bosari S, Viale G (1995) The clinical significance of p53 aberrations in human tumours. Virchows Arch 427:229–241

    PubMed  Google Scholar 

  • Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen, J, Brennan MF, Levine JL (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54:794–799

    PubMed  Google Scholar 

  • Dolcetti R, Doglioni C, Maestro R, Gasparotto D, Barzan L, Pastore A, Romanelli M, Bolocchi M (1992) p53 over-expression is an early event in the development of human squamous-cell carcinoma of the larynx: genetic and prognostic implications. Int J Cancer 52:178–182

    PubMed  Google Scholar 

  • Drobnjak M, Latres E, Pollack D, Karpeh M, Dudas M, Woodruff JM, Brennan MF, Cardon-Cardo C (1994) Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft tissue sarcomas. J Natl Cancer Inst 86:549–554

    PubMed  Google Scholar 

  • Ebina M, Steinberg SM, Mulshine JL, Linnoila RI (1994) Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54:2496–2503

    PubMed  Google Scholar 

  • Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC (1994) p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res 54:3752–3757

    PubMed  Google Scholar 

  • Enzinger FM, Weiss SW (1995) Soft tissue tumors, 3rd edn. Mosby, St. Louis, pp 1–16, 131–164, 269–292, 351–380, 431–466, 491–510, 539–578, 889–928

    Google Scholar 

  • Gottlieb MG, Oren M (1996) p53 in growth control and neoplasie. Biochim Biophys Acta 1287:77–102

    PubMed  Google Scholar 

  • Hall PA, Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? — revised! J Pathol 172:1–4

    PubMed  Google Scholar 

  • Harris C (1996) p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17:1187–1198

    PubMed  Google Scholar 

  • Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TWJ, Horne CHW (1996) p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29–35

    PubMed  Google Scholar 

  • Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumor supressor gene protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114

    PubMed  Google Scholar 

  • Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmüller G, Scherer E, Maurer J, Maacke H, Deppert W (1993)p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 8:289–298

    PubMed  Google Scholar 

  • Kawai A, Noguchi M, Beppu Y, Yokoyama R, Mukai K, Hirohashi S, Inoue H, Fukuma H (1994) Nuclear immunoreaction of p53 protein in soft tissue sarcomas. Cancer 73:2499–2505

    PubMed  Google Scholar 

  • Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP (1996) Structure of the MDM2 oncoproteine bound to the p53 tumor suppressor transactivation domain. Science 274:948–953

    PubMed  Google Scholar 

  • Lambkin HA, Mothershill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression in cervical tumours with different antibodies and methods of detection. J Pathol 172:13–18

    PubMed  Google Scholar 

  • Latres E, Drobnjak M, Pollack D, Oliva MR, Ramos M, Karpeh M, Woodruff JM, Cordon-Cardo C (1994) Chromosome 17 abnormalities and p53 mutation in adult soft tissue sarcomas. Am J Pathol 145:345–354

    Google Scholar 

  • Leach FS, Tokino T, Metzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 mutation and mdm2 amplification in human soft tissue sarcomas. Cancer Res 53:2231–2234

    PubMed  Google Scholar 

  • Legros Y, Lacabanne V, d'Agay MF, Larsen CJ, Pla M, Soussi T (1993) Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull Cancer 80:102–110

    PubMed  Google Scholar 

  • Ling J, Chen J, Elenbaas B, Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm2 and the adenovirus 5 E1B 55-kD-protein. Genes Dev 8:1235–1246

    PubMed  Google Scholar 

  • McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66:735–738

    PubMed  Google Scholar 

  • Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM (1992) Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed inEscherichia coli. J Cell Sci 101:183–189

    PubMed  Google Scholar 

  • Mousses S, McAuley L, Bell RS, Kandel R, Andrulis IL (1996) Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mod Pathol 9:1–6

    PubMed  Google Scholar 

  • Niemann TH, Raab SS, Lenel JC, Rodgers JR, Robinson RA (1995) p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol 26:375–379

    PubMed  Google Scholar 

  • Ohuc M, Tomita N, Monden T, Fujita M, Fukunaga M, Takami KA (1994) Frequent alteration of p53 gene in carcinoma in adenoma of colon. Cancer Res 54:4798–4804

    PubMed  Google Scholar 

  • Oshiro Y, Fukuda T, Tsuneyoshi M (1994) Fibrosarcoma versus fibromatoses and cellular nodular fasciitis. A comparative study of their proliverative activity using proliferating cell nuclear antigen, DNA flow cytometry, and p53. Am J Surg Pathol 18:712–719

    PubMed  Google Scholar 

  • Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CDM, Thomas M, Grimer R, Gusterson BA, Cooper CS (1994) Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 69:1052–1058

    PubMed  Google Scholar 

  • Reid AH, Tsai MS, Venzon DJ, Wright CF, Lack EE, O'Leary TJ (1996) MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 5:65–73

    PubMed  Google Scholar 

  • Said J, Barrera R, Shintaku IP, Nakamura H, Koeffler HP (1992) Immunohistochemical analysis of p53 expression in malignant lymphomas. Am J Pathol 141:1343–1348

    PubMed  Google Scholar 

  • Segers K, Backhovens H, Singh SK, de Voecht J, Ramael M, van Broeckhoven C, van Marck E (1995) Immunoreactivity for p53 and mdm2 and the detection of mutations in human malignant mesothelioma. Virchows Arch 427:431–436

    PubMed  Google Scholar 

  • Stephen CW, Lane DP (1992) Mutant conformation of p53 Precise epitope mapping using filamentous phage epitope library. J Mol Biol 225:577–583

    PubMed  Google Scholar 

  • Stephen CW, Helminen P, Lane DP (1995) Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insight into antibody-peptide interactions. J Mol Biol 248:58–78

    PubMed  Google Scholar 

  • Stürzbecher HW, Addison C, Jenkins JR (1988) Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 8:3740–3747

    PubMed  Google Scholar 

  • Taubert H, Würl P, Meye A, Berger D, Thamm B, Neumann K, Hinze R, Schmidt H, Rath FW (1995) Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Cancer 76:1187–1196

    PubMed  Google Scholar 

  • Taubert H, Meye A, Würl P (1996) Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 56:4134–4136

    PubMed  Google Scholar 

  • Toffoli G, Doglioni C, Cernigoi C, Frustaci S, Perin T, Canal B, Boiocchi M (1994) p53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. Ann Oncol 5:167–172

    PubMed  Google Scholar 

  • Tominaga O, Hamelin R, Trouvat V, Salmon RJ, Lesec G, Thomas G, Remvikos Y (1993) Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene 8:2553–2558

    Google Scholar 

  • Unger T, Nau MM, Segal S, Minna JD (1992) p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J 11:1383–1390

    PubMed  Google Scholar 

  • Unnik JAM van, Coindre JM, Contesso G, Albus-Lutter CE, Schiodt T, Garcia-Miralles T (1988) Grading of soft tissue sarcomas. In: Ryan JR, Baker LO (eds) Experience of the EORTC soft tissue and bone sarcoma treatment. Kluwer Academic, Dordrecht, pp 7–13

    Google Scholar 

  • Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244

    PubMed  Google Scholar 

  • Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA, Lane DP (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10:389–393

    PubMed  Google Scholar 

  • Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y, Yamamuro T (1993) p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68:1134–1139

    PubMed  Google Scholar 

  • Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I (1994) High prevalence of p53 overexpression in patients with oesophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74:3089–3096

    PubMed  Google Scholar 

  • Watanabe R, Tomita Y, Nishiyama T, Tanikawa T, Sato S (1994) Correlation of p53 protein expression in urothelial transitional cell cancers with malignant potential and patient survival. Int J Urol 1:43–48

    PubMed  Google Scholar 

  • Würl P, Taubert H, Bache M, Kroll J, Meye A, Siermann A, Holzhausen H-J, Hinze R, Schmidt H, Rath F-W (1996) Frequent occurrence of p53 mutations in rhabdo- and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69:317–323

    PubMed  Google Scholar 

  • Wynford-Thomas D (1992) p53 in tumour pathology: can we trust immunocytochemistry. J Pathol 166:329–330

    PubMed  Google Scholar 

  • Yang P, Hirose T, Hasegawa T, Seki K, Sano T, Hizawa K (1995) Prognostic implication of the p53 protein and K-67 antigen: immunohistochemistry in malignant fibrous histiocytoma. Cancer 76:618–625

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of General Surgery, Martin Luther University of Halle-Wittenberg, Halle/Saale, Germany

    Peter Würl & Henning Dralle

  2. Institute of Pathology, Martin Luther University of Halle-Wittenberg, Magdeburger Str. 14, D-06097, Halle/Saale, Germany

    Helge Taubert, Axel Meye, Dieter Berger, Hans-Jürgen Holzhausen & Hannelore Schmidt

  3. Institute of Biometry and Informatics, Martin Luther University of Halle-Wittenberg, Halle/Salle, Germany

    Christine Lautenschläger & Friedrich-Wilhelm Rath

  4. Clinic General Surger, Christian Albrechts, University of Kiel, Kiel, Germany

    Holger Kalthoff

Authors
  1. Peter Würl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helge Taubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Axel Meye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dieter Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Lautenschläger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans-Jürgen Holzhausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hannelore Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Holger Kalthoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Friedrich-Wilhelm Rath
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Henning Dralle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helge Taubert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Würl, P., Taubert, H., Meye, A. et al. Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 123, 502–508 (1997). https://doi.org/10.1007/BF01192205

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01192205

Key words

Search

Navigation